SIGN UP
LOG IN
A
01672
Ascletis Pharma
6.18
-0.10-1.59%Opening15:04 04/28 HKT
OPEN/PREV CLOSE6.200/6.280
TODAY RANGE5.930-6.270
VOL1.71M
MARKET CAP5.99B
52 WEEK RANGE0.760-9.280
AVG VOL (3M)7.40M
% TURNOVER0.18%
TURNOVER10.44M
P/E (TTM)-18.318
% RANGE5.41%
EPS(TTM)-0.337
P/E(FORWARD)-14.514
P/B2.804
BVPS2.204
DIVIDEND--
P/S97.940
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP5.95B
SHARES OUTSTANDING969.02M
NEXT EARNINGS--
FREE FLOAT963.24M
LOT SIZE1000
EX-DIV DATE--
News
Press Releases
Financial Reports
Profile
Reuters·03/12 06:31
BUZZ-China's Ascletis hits 6-year peak on good results for weight loss drug
Simply Wall St·02/19 22:26
Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation
Reuters·02/19 12:00
ASCLETIS PHARMA INC - COHORT 3 EXPECTED TO BE COMPLETED BY END OF MARCH 2025
Simply Wall St·01/16 22:26
Bullish Ascletis Pharma Insiders Rewarded As Their Investment Rises To CN¥37.4m
Simply Wall St·12/17/2024 00:54
The recent 19% gain must have brightened CEO Jinzi Jason Wu's week, Ascletis Pharma Inc.'s (HKG:1672) most bullish insider
Reuters·11/12/2024 11:30
ASCLETIS PHARMA INC - TOPLINE RESULTS EXPECTED IN Q2 2025
Simply Wall St·11/11/2024 23:49
Ascletis Pharma (HKG:1672) shareholders are up 17% this past week, but still in the red over the last five years
Reuters·11/07/2024 11:30
ASCLETIS PHARMA INC - ASC47 SHOWS MUSCLE-PRESERVING WEIGHT LOSS IN PRE-CLINICAL STUDIES
Reuters·10/07/2024 01:04
BRIEF-Ascletis Pharma Says Got Initial Determination From US International Trade Commission
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.